Yumanity Therapeutics, Inc.

Kronos Bio, Inc. implemented a restructuring plan in November that resulted in a 19% workforce reduction but extended its cash runway into 2026 and the company unveiled further cost cuts on 7 March t

Less than two years after going public via a reverse merger with troubled cystic fibrosis company Proteostasis Therapeutics, Inc. , Yumanity Therapeutics, Inc. is winding up its operations by selli

The ongoing financial market turmoil for biopharma has put an end to Amicus Therapeutics, Inc. ’s plan to spin out its gene therapy business in a separate publicly traded company called Caritas Ther

Merck & Co., Inc. is looking to see how the US Food and Drug Administration’s openness to using biomarkers in Alzheimer’s disease drug development may affect its programs. During its 29 July second q